Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07XGR
|
||||
| Former ID |
DAP000270
|
||||
| Drug Name |
Fenofibrate
|
||||
| Synonyms |
Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antilipemic Agents
|
||||
| Company |
Abbott Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H21ClO4
|
||||
| InChI |
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
|
||||
| InChIKey |
YMTINGFKWWXKFG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 49562-28-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9788, 143271, 855565, 3718278, 5309234, 7847631, 7979221, 8149697, 8152122, 10321317, 10852041, 11111181, 11111182, 11335732, 11360971, 11364144, 11366706, 11369268, 11372481, 11373845, 11377430, 11461943, 11466303, 11467423, 11485116, 11486105, 11489206, 11491246, 11492228, 11495064, 11528711, 11533532, 14901407, 17405049, 22395205, 24278015, 26612151, 26680406, 26746914, 26746915, 26751450, 29222474, 46507371, 47291103, 47291104, 47365158, 47515293, 47662254, 47736448, 47810726
|
||||
| ChEBI ID |
ChEBI:5001
|
||||
| SuperDrug ATC ID |
C10AB05
|
||||
| SuperDrug CAS ID |
cas=049562289
|
||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor alpha | Target Info | Agonist | [534997] | |
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | RORA activates gene expression | ||||
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||||
| PPARA activates gene expression | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Transcriptional activation of mitochondrial biogenesis | |||||
| Activation of gene expression by SREBF (SREBP) | |||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Circadian Clock | |||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Estrogen Receptor Pathway | |||||
| PPAR Alpha Pathway | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Circadian Clock | |||||
| Nuclear Receptors | |||||
| References | |||||
| Ref 536740 | Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. | ||||
| Ref 542197 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7186). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.